Guéry J C, Neagu M, Rodriguez-Tarduchy G, Adorini L
Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
J Exp Med. 1993 May 1;177(5):1461-8. doi: 10.1084/jem.177.5.1461.
The self-mouse lysozyme peptide corresponding to residues 46-62 (ML46-62) binds to the major histocompatibility complex (MHC) class II molecules I-A(k) and it selectively inhibits, when coinjected with antigen, priming of I-A(k)-restricted, antigen-specific T cells. We demonstrate that administration of ML46-62 also inhibits in vivo antibody responses induced by I-A(k)-restricted T helper cells. ML46-62 is able to prevent the primary anti-hen egg white lysozyme (HEL) antibody response induced by the entire HEL molecule in B10.A(4R) mice, expressing only I-A(k) molecules, but not in mice of H-2d haplotype. ML46-62 also strongly decreases, in B10.A(4R) mice, the antibody response to ribonuclease A, a protein antigen unrelated to the MHC blocker, indicating that MHC blockade is the mechanism leading to inhibition of antibody response. This is further supported by the concomitant decrease, in vivo, of complex formation between immunodominant HEL peptides and I-A(k) molecules, preventing I-A(k)-restricted T cell induction. Administration of ML46-62 after antigen priming does not affect ongoing antibody responses, as expected from MHC blockade. A single injection of ML46-62 at the time of protein antigen priming precludes not only the primary, but also the secondary antibody response to a subsequent challenge with soluble protein, even when the challenge is performed several months after priming. Coinjection of antigen and MHC antagonist inhibits production of all antibody isotypes equally well, suggesting that MHC class II blockade affects both Th1- and Th2-type T helper cells. Therefore, these results indicate that administration of MHC class II-binding peptides can efficiently and selectively prevent the induction of T cell-dependent primary and secondary in vivo antibody responses by blocking antigen presentation to class II-restricted T helper cells.
与46 - 62位氨基酸残基对应的自身小鼠溶菌酶肽(ML46 - 62)与主要组织相容性复合体(MHC)II类分子I - A(k)结合,并且当与抗原共同注射时,它能选择性地抑制I - A(k)限制的、抗原特异性T细胞的致敏。我们证明,给予ML46 - 62也能在体内抑制由I - A(k)限制的T辅助细胞诱导的抗体反应。ML46 - 62能够阻止仅表达I - A(k)分子的B10.A(4R)小鼠中由完整的蛋清溶菌酶(HEL)分子诱导的初次抗HEL抗体反应,但不能阻止H - 2d单倍型小鼠的该反应。在B10.A(4R)小鼠中,ML46 - 62还能显著降低对核糖核酸酶A(一种与MHC阻断剂无关的蛋白质抗原)的抗体反应,这表明MHC阻断是导致抗体反应抑制的机制。免疫显性HEL肽与I - A(k)分子之间的复合物形成在体内同时减少,从而阻止了I - A(k)限制的T细胞诱导,这进一步支持了上述观点。正如MHC阻断所预期的那样,在抗原致敏后给予ML46 - 62不会影响正在进行的抗体反应。在蛋白质抗原致敏时单次注射ML46 - 62不仅能阻止初次抗体反应,还能阻止对随后可溶性蛋白质攻击的二次抗体反应,即使攻击在致敏后数月进行。抗原与MHC拮抗剂共同注射能同等程度地抑制所有抗体亚型的产生,这表明II类MHC阻断会影响Th1型和Th2型T辅助细胞。因此,这些结果表明,给予与II类MHC结合的肽可以通过阻断抗原呈递给II类限制的T辅助细胞,有效地、选择性地预防体内T细胞依赖性初次和二次抗体反应的诱导。